Issue 142 | May 2024
Anticipation rises for RSV rollout as positive data emerges
In this issue: Following the RSV therapy and vaccine rollout, understanding molecular glues, using pharmacovigilance for active drug discovery, BARDA’s plans to combat multiple infections, and more.